Last Chance: This New Profile (EVAHF) Released Huge News Last Week, Requires Immediate Attention (Low Float)
U.S. OTC: (EHAVF) - Canada CSE: (TMED)
Psi-loc-ybin is one of the most effective psych-e-delics for the treatment of conditions such as treatment-resistant depression, anxiety, PTSD and depression.
These natural benefits, known for years to traditional societies, are only now being researched after decades of stigmatization and inaccurate scaremongering.
The world’s leading academic institutions are compiling a growing amount of research into the benefits of psi-lo-cybin.
Universities such as Imperial College London, the NYU Grossman School of Medicine and Johns Hopkins University, and medical research bodies including the Heffter Research Institute, the Beckley Foundation and MAPS have all contributed to this.
But, let's dive in a little deeper...
Mental Health - Key Statistics To Know Now
Take a breath and try to wrap your head around this (Sources 1 & 2):
- 25% - Global population with mental health/neurological disorders
- 450M - People with inadequate first-line treatment options
- 75% - Of people with serious substance abuse with inadequate treatment
- $10B - Current global market for DPS treatment
- $128.9Bn - Projected global market for mental health/neurological disorders in 2025
- 1 in 11 - People will suffer from PTSD at some point in their lives
Let's face it, these figures are unacceptable.
To try and combat these mental health issues, there's one company flying under Wall Street's radar that may turn out to be a true game-changer in the space.
For Monday, June 28th, there is only one profile to have at the top of your watch-list:
EGF Theramed Health Corp. (EVAHF)
EGF Theramed Health is positioning itself at the frontier of medical science.
Psych-e-delic dr-ugs are gathering support as a bona fide treatment for mental health problems, one of the most pressing and costly crises facing the modern world.
EVAHF is exploring every opportunity on offer in this new area of research, forming partnerships with pioneering companies.
Their current focus is on the psil-o-cybin space, looking at methods of improving delivery systems for the compound, and creating strong intellectual property.
The company explores many other medical areas including weight loss, skin care and heart disease.
EGF Theramed Health Corp. also trades on the Canadian Securities Exchange under the symbol (CSE: TMED).
EVAHF Portfolio: Pharmadelic Labs & Green Parrot Labs
On May 6th, 2020, Theramed acquired a 30% stake in Pharmadelic Labs.
Pharmadelic Labs is a biotech company focusing on improving and patenting engineering processes for the biosynthesis of compounds - primarily psi-lo-cybin, the psych-o-active component of magic mush-rooms.
Now, leading scientists, academic institutions and government administrations are turning their attention to the benefits of psi-lo-cybin as a potential treatment for the global problems of mental health and end of life care. The ability to produce this molecule quickly, economically and cleanly, as Pharmadelic Labs is aiming to achieve, will be in high demand when psi-loc-ybin gains widespread acceptance.
Green Parrot Labs
On May 22nd, 2020, EGF Theramed acquired a 40% stake in Green Parrot Labs.
Green Parrot Labs is a company with operations based in the Caribbean, offering wellness centers and research and development into biosynthesis pathways for psi-lo-cybin and cann-a-binoids.
The two operations of the company take advantage of the generous laws in Barbados, Jamaica and the British Virgin Islands towards medical tourism and research into rare compounds.
Green Parrot will be offering services providing a tailored treatment program for individuals suffering from inflammatory bowel disease (IBD) in specialized wellness centers.
The research and development facilities will be aimed at producing biosynthesis pathways that can be licensed across the world, and used in the wellness centers.
And, right now, this profile has multiple potential driver indicators that could signal an upcoming vertical move on the horizon.
None may be bigger than Friday afternoon's huge news. Check it out.
Top Potential Driver Indicator - Pharmadelic Labs Signs Services Agreement
EGF Theramed Joint Venture Partner Pharmadelic Labs Announces Lab Services Agreement With Numinus Wellness
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - EGF Theramed Health Corp. (CSE: TMED) (OTC Pink: EVAHF) ("Theramed", the "Company") is pleased to announce that its subsidiary joint venture Pharmadelic Labs Inc. ("Pharmadelic") has signed a laboratory services agreement with Numinus Wellness Inc. (TSXV: NUMI) ("Numinus").
Pharmadelic is a biotech company focused on developing, improving and patenting engineering processes for the biosynthesis of compounds, primarily psi-lo-cybin. Through the Health Canada-licensed Numinus Bioscience lab in British Columbia, Canada, Numinus will provide Pharmadelic with lab expertise and R&D services such as analytical, purity and compound identification testing along with regulatory and compliance consulting services.
Pharmadelic aims to develop a portfolio of intellectual property around biosynthesis pathways using yeast and psi-lo-cybin. By editing the genome sequences of industrial brewing yeasts, the company plans to create commercially viable compounds derived from psi-lo-cybin. The expected advantages of this method include:
- significantly quicker than growing and extracting from mush-rooms (days rather than weeks)
- safe, through the use of GRAS (Generally Recognized As Safe) products ready for use in industry
- a controlled and uniform level of psi-lo-cybin throughout the finished product
- much cheaper to produce on a mass scale than greenhouse growing
"The agreement with Numinus accelerates and expands Pharmadelic's ability to produce valuable intellectual property and increase shareholder value for both Pharmadelic and TMED," said George Anstey, CEO of Pharmadelic Labs Corp and director of EGF Theramed. "We look forward to working with Numinus to drive our R&D agenda and create and support the advancement of health and wellness for all."
Pharmadelic will work with a wide range of partners across multiple industries, starting with pharmaceutical companies creating products for the nascent psych-e-delics market.Under Canada's Controlled Dr-ugs and Substances Act, Numinus Bioscience can possess, produce, assemble, sell, export, and deliver a wide variety of psych-e-delics...[...].
The laboratory provides internationally acclaimed analytical and natural product chemists, biochemists, molecular biologists and quality management experts, state-of-the-art equipment and proprietary methods to ensure validated results and finished products.
The specific terms of the two-year agreement are private. Numinus Wellness has taken an equity position in Pharmadelic. The agreement was signed May 28, 2021. The agreement is subject to certain requirements.
Read the full article here.
Potential Driver Indicator - Explosive Chart History
Just take a look at EVAHF's 1-year chart: